AR074691A1 - Derivados de tiazol como ligandos de receptores de cannabinoides - Google Patents
Derivados de tiazol como ligandos de receptores de cannabinoidesInfo
- Publication number
- AR074691A1 AR074691A1 ARP090104914A ARP090104914A AR074691A1 AR 074691 A1 AR074691 A1 AR 074691A1 AR P090104914 A ARP090104914 A AR P090104914A AR P090104914 A ARP090104914 A AR P090104914A AR 074691 A1 AR074691 A1 AR 074691A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr1cr1d
- alkyl
- haloalkyl
- orf
- case
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones que comprenden dichos compuestos y métodos para tratar condiciones y trastornos usando dichos compuestos y composiciones. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1), o una sal, solvato o sal de un solvato aceptable farmacéuticamente del mismo, donde L1 es O, S, S(O), S(O)2, o N(Rbx); donde Rbx es hidrógeno, alquilo, haloalquilo, alcoxialquilo, -C(O)O(alquilo), cicloalquilo monocíclico, -(CR1cR1d)q3- (cicloalquilo monocíclico), o haloalcoxialquilo; y A1 es -G1a-G1b, -(CR1aR1b)q1-G1c; -G1e, -(CR1aR1b)q1-A2, -N(Rb)C(O)Ra, -N(Rb)C(O)ORd, -N(Rb)C(O)N(Rb)(Rc), -N(Rb)(Rc), o -N=C(Rp)(Rq); o L1 y A1 juntos son N=N(Rcx); donde Rcx es alquilo, haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rp es hidrógeno, alquilo, haloalquilo, -(CR1aR1b)q3-A3, -C(O)ORd, -C(O)Rd, G1d, o -(CR1aR1b)q3-G1d; Rq es hidrógeno, alquilo, haloalquilo, -N(Rb)(Rc), -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; o Rp y Rq, junto con el átomo de carbono al cual se encuentran unidos, forman un anillo de 5, 6, 7 u 8 miembros seleccionado entre el grupo que consiste en cicloalquilo monocíclico y heterociclo monocíclico, opcionalmente sustituido con 1, 2, 3, 4, o 5 sustituyentes seleccionados independientemente entre el grupo que consiste en oxo, alquilo, haloalquilo, y halógeno; A2 es -C(O)Ra, -S(O)2Rd, -C(O)N(Rb)Rc), -C(S)N(Rb)(Rc), -S(O)2N(Rb)(Rc), -C(=NORf)Ra, -CN, -N(Rc)C(O)Ra, -N(Rc)C(O)ORd, -N(Rc)S(O)2Rd, -N(Rc)C(O)N(Rb)(Rc), -N(Rc)S(O)2N(Rb)(Rc), -N(Rb)(Rc), -O-Rj, o -O-C(O)(alquilo); Ra y Rc, en cada caso, son independientemente entre sí hidrógeno, alquilo, haloalquilo, -(CR1aR1b)q2-A3, G1d, o -(CR1aR1b)q2-G1d; Rb, en cada caso, es independientemente hidrógeno, alquilo, haloalquilo, alcoxialquilo, cicloalquilo monocíclico, -(CR1cR1d)q2-(cicloalquilo monocíclico), o haloalcoxialquilo; Rd en cada caso, es independientemente alquilo, haloalquilo, -(CR1aR1b)q2-A3, G1d, o -(CR1aR1b)q2-G1d; Rj es hidrógeno, haloalquilo, -(CR1aR1b)q2-A3, G1d, o -(CR1aR1b)q2-G1d; A3 es C(O)Rh, -S(O)2Re, -C(O)N(Rh)2, -C(S)N(Rh)2, -S(O)2N(Rh)2, -C(=NORh)Rh, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, -N(Rh)S(O)2Re, -N(Rh)C(O)N(Rh)2, -N(Rh)S(O)2N(Rh)2, -CN, -ORh, o -N(Rh)2; G1a, G1b, y G1c, en cada caso, son independientemente entre sí cicloalquilo, cicloalquenilo, heterociclo, arilo, o heteroarilo; G1e es cicloalquilo, heterociclo, o heteroarilo; donde el anillo según se lo representa mediante G1a se sustituye opcionalmente con 1, 2, 3, 4 o 5 sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo, alquenilo, alquinilo, halógeno, haloalquilo, =N-CN, =N-ORf, -CN, oxo, -ORf, -OC(O)Rf, -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, -N(Rf)S(O)2Re, -N(Rf)C(O)O(Re), -N(Rf)C(O)N(Rf)2, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2 y -(CR1cR1d)q3-CN; donde los anillos según se los representa mediante G1b y G1c se sustituye cada uno opcionalmente con 1, 2, 3, 4, o 5 sustituyentes seleccionados independientemente entre el grupo que consiste en -G1d, -(CR1cR1d)q3-G1d, alquilo, alquenilo, alquinilo, halógeno, haloalquilo, =N-CN, =N-ORf , -CN, oxo, -ORf, -OC(O)Rf, -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, -N(Rf)S(O)2Re, -N(Rf)C(O)O(Re), -N(Rf)C(O)N(Rf)2, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2 y -(CR1cR1d)q3-CN; donde el anillo según se lo representa mediante G1e se sustituye opcionalmente con 1, 2, 3, 4, o 5 sustituyentes seleccionados independientemente entre el grupo que consiste en -(CR1cR1d)q3-G1d, alquilo, alquenilo. alquinilo, halógeno, haloalquilo, =N-CN, =N-ORf , -CN, oxo, -ORf, -OC(O)Rf, -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, -N(Rf)S(O)2Re, -N(Rf)C(O)O(Re), -N(Rf)C(O)N(Rf)2, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2 y -(CR1cR1d)q3-CN; G1d, en cada caso, es independientemente un heterociclo monocíclico, un heteroarilo monocíclico, un fenilo, un cicloalquilo monocíclico, o un cicloalquenilo monocíclico; cada uno de los cuales se sustituye opcionalmente con 1, 2, 3, o 4 sustituyentes seleccionados independientemente entre el grupo que consiste en -N(Rh)2, -CN, oxo, alquilo, haloalquilo, alcoxi, haloalcoxi, halógeno, y hidroxi; Re y Ri, en cada caso, son independientemente entre si alquilo C1-4, haloalquilo C1-4, cicloalquilo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); Rf en cada caso, es independientemente hidrógeno, alquilo C1-4, haloalquilo C1-4, -(CR1cR1d)q3-ORg, cicloalquilo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); Rg y Rh, en cada caso, son independientemente entre sí hidrógeno, alquilo C1-4, haloalquilo C1-4, cicloalquilo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); donde el cicloalquilo monocíclico, como un sustituyente o parte de un sustituyente, de Rbx, Rb, Re, Ri, Rf, Rg, y Rh, en cada caso, independientemente no se sustituye o se sustituye con 1, 2, 3, o 4 sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-4, halógeno, oxo, hidroxi, alcoxi, C1-4, haloalcoxi C1-4, y haloalquilo C1-4; R2 es alquilo C2-10, alquenilo, alquinilo, haloalquilo, -(CR2aR2b)q4-O-haloalquilo, -(CR2aR2b)q4-O-G2a, -(CR2aR2b)q4-O-(CR2cR2d)q5-G2a, -(CR2aR2b)q5-C(O)-Ra, -(CR2aR2b)q5-C(=N-ORe)Ra, -(CR2aR2b)q5-SO2-Rd, -(CR2aR2b)q5-G2b, -(CR2aR2b)q5-C(O)N(Rb)(Rc), -(CR2aR2b)q4-OC(O)N(Rb)(Rc), o -(CR2aR2b)q5-CN; G2a, en cada caso, es independientemente cicloalquilo, cicloalquenilo, heterociclo, arilo, o heteroarilo; G2b es cicloalquilo, cicloalquenilo, tien-2-ilo, o tien-3-ilo, donde los anillos según se los representa mediante G2a y G2b se sustituye cada uno opcionalmente con 1, 2, 3, 4, o 5 sustituyentes seleccionados independientemente entre el grupo que consiste en oxo, alquilo, halógeno, hidroxi, alcoxi, haloalcoxi, y haloalquilo; R3 y R4 son iguales o diferentes, y son independientemente entre sí G3, hidrógeno, alquilo, alquenilo, alquinilo, -NO2, -CN, halógeno, -ORh, -N(Rh)2, -C(O)Rh, -C(O)O(Rh), haloalquilo, -(CR3aR3b)q6-ORh, -(CR3aR3b)q6-N(Rh)2, -(CR3aR3b)q6-C(O)Rh, o -(CR3aR3b)q6-C(O)O(Rh); o R3 y R4, junto con los átomos de carbono a los cuales se encuentran unidos, forman un anillo monocíclico de 4, 5, 6 o 7 miembros que contiene cero, una, o dos uniones dobles adicionales, que contiene opcionalmente uno o dos átomos de nitrógeno como átomos del anillo, dos átomos no adyacentes del anillo monocíclico se unen opcionalmente mediante un puente alquenileno de 2, 3, o 4 átomos de carbono, o se unen opcionalmente mediante un puente alquileno de 1, 2, 3, o 4 átomos de carbono, el anillo monocíclico no se sustituye o se sustituye con 1, 2, 3, 4, o 5 sustituyentes seleccionados independientemente entre el grupo que consiste en oxo, alquilo, halógeno, hidroxi, alcoxi, haloalcoxi, y haloalquilo; dos sustituyentes sobre el mismo átomo de carbono de dicho anillo monocíclico, junto con el átomo de carbono al cual se encuentran unidos, forman opcionalmente un anillo cicloalquilo monocíclico de 3, 4, 5 o 6 miembros, donde el anillo cicloalquilo monocíclico se sustituye opcionalmente con 1, 2, 3, 4, 5, o 6 sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo y haloalquilo; G3 es cicloalquilo, cicloalquenilo, arilo, heterociclo, o heteroarilo, cada uno de los cuales no se sustituye o se sustituye independientemente con 1, 2, 3, o 4 sustituyentes seleccionados independientemente entre el grupo que consiste en alquilo C1-4, alquenilo C2-4, alquinilo C2-4, halógeno, haloalquilo C1-4, =N-CN, =N-ORh, -CN, oxo, -ORh, -OC(O)Rh, -OC(O)N(Rh)2, -S(O)2Ri, -S(O)2N(Rh)2, -C(O)Rh, -C(O)ORh, -C(O)N(Rh)2, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)S(O)2Ri, -N(Rh)C(O)O(Ri), y -N(Rh)C(O)N(Rh)2; R1a, R1c, R1d, R2a, R2b, R2c, R2d, R3a, y R3b, en cada caso, son independientemente entre sí hidrógeno, halógeno, alquilo C1-4, o haloalquilo C1-4; R1b, en cada caso, es independientemente hidrógeno, halógeno, alquilo C1-4, haloalquilo C1-4, -ORh, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, o -N(Rh)S(O)2Re; R1g, en cada caso, es independientemente G1d, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, halógeno, haloalquilo C1-4, -CN, -ORf, OC(O)Rf, -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, -N(Rf)S(O)2Re, -N(Rf)C(O)O(Re), -N(Rf)C(O)N(Rf)2, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2 o -(CR1cR1d)q3-CN; q1 y q2, en cada caso, son independientemente entre sí 1, 2. 3, o 4; q3, en cada caso, es independientemente 1, 2 o, 3; q4, en cada caso, es independientemente 2, 3, 4, o 5; q5 y q6, en cada caso, son independientemente entre sí 1, 2, 3, 4, 5, o 6; y z es 0, 1, 2, 3, o 4; con la condición de que cuando L1 es N(Rbx) donde Rbx es hidrógeno, alquilo, o alcoxialquilo; y R2 alquilo C2-10, alquenilo, alquinilo, haloalquilo, -(CR2aR2b)q5-C(O)-Ra donde Ra es heterociclo, -(CR2aR2b)q5-C(O)N(Rb)(Rc) donde Rb y Rc son hidrógeno o alquilo, -
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12295908P | 2008-12-16 | 2008-12-16 | |
US22420209P | 2009-07-09 | 2009-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR074691A1 true AR074691A1 (es) | 2011-02-02 |
Family
ID=41539301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104914A AR074691A1 (es) | 2008-12-16 | 2009-12-16 | Derivados de tiazol como ligandos de receptores de cannabinoides |
Country Status (12)
Country | Link |
---|---|
US (1) | US8895592B2 (es) |
EP (2) | EP3026046A1 (es) |
JP (1) | JP2012512253A (es) |
CN (1) | CN102574825A (es) |
AR (1) | AR074691A1 (es) |
CA (1) | CA2745459A1 (es) |
ES (1) | ES2564091T3 (es) |
MX (1) | MX2011006343A (es) |
PA (1) | PA8854001A1 (es) |
TW (1) | TW201024291A (es) |
UY (1) | UY32331A (es) |
WO (1) | WO2010071783A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090018685A (ko) * | 2006-05-31 | 2009-02-20 | 아보트 러보러터리즈 | 칸나비노이드 수용체 리간드로서의 티아졸 화합물 및 이의 용도 |
US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
CA2647598A1 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
CA2681586A1 (en) | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US7872033B2 (en) * | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
CN101711253A (zh) | 2007-05-18 | 2010-05-19 | 雅培制药有限公司 | 用作大麻素受体配体的新化合物 |
US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
JP2011513495A (ja) | 2008-03-11 | 2011-04-28 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
EP2428507B1 (en) | 2008-09-16 | 2015-10-21 | AbbVie Bahamas Ltd. | Cannabinoid receptor ligands |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
TW201130855A (en) * | 2009-12-16 | 2011-09-16 | Abbott Lab | Prodrug compounds useful as cannabinoid ligands |
WO2011075525A1 (en) * | 2009-12-16 | 2011-06-23 | Abbott Laboratories | Process for preparing cannabinoid receptor ligands |
WO2013049407A2 (en) * | 2011-09-30 | 2013-04-04 | Kineta, Inc | Anti-viral compounds |
CA3015345A1 (en) | 2016-02-23 | 2017-08-31 | Indiana University Research & Technology Corporation | Combination therapies for treatment of spinal muscular atrophy |
CN111732594B (zh) * | 2020-08-18 | 2022-03-04 | 苏州富士莱医药股份有限公司 | 一种氟唑帕利的制备方法 |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1522361A1 (de) | 1966-03-08 | 1969-07-24 | Agfa Gevaert Ag | Sensibilisierung lichtempfindlicher Polymerer |
US3557142A (en) * | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
DE1772867A1 (de) | 1968-07-15 | 1971-06-16 | Agfa Gevaert Ag | Sensibilisierung von Schichten aus lichtvernetzbaren Polymeren |
JPS5089367A (es) | 1973-12-14 | 1975-07-17 | ||
JPS57171986A (en) | 1981-04-14 | 1982-10-22 | Taiho Yakuhin Kogyo Kk | Heterocylic ring compound containing sulfur |
DE3333450A1 (de) * | 1983-09-16 | 1985-04-11 | Hoechst Ag, 6230 Frankfurt | Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt |
US4978664A (en) * | 1984-08-06 | 1990-12-18 | Sterling Drug Inc. | 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indole pharmaceutical compositions |
US4885295A (en) * | 1984-08-06 | 1989-12-05 | Sterling Drug Inc. | Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles |
DE3533331A1 (de) | 1985-09-18 | 1987-03-26 | Heumann Ludwig & Co Gmbh | Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3807381A1 (de) * | 1988-03-07 | 1989-09-21 | Hoechst Ag | 4,6-bis-trichlormethyl-s-triazin-2-ylgruppen enthaltende heterocyclische verbindungen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindung enthaelt |
TW205041B (es) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
DE4021439A1 (de) * | 1989-12-14 | 1991-06-20 | Bayer Ag | 2-iminopyridin-derivate |
US6559186B1 (en) * | 1990-02-26 | 2003-05-06 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
US5013837A (en) * | 1990-03-08 | 1991-05-07 | Sterling Drug Inc. | 3-Arylcarbonyl-1H-indole-containing compounds |
US4973587A (en) * | 1990-03-08 | 1990-11-27 | Sterling Drug Inc. | 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method |
EP0639569A4 (en) | 1991-03-11 | 1995-09-20 | Nippon Soda Co | NEW HETEROCYCLIC COMPOUND. |
WO1993018031A1 (en) * | 1992-03-03 | 1993-09-16 | Idemitsu Kosan Co., Ltd. | Pyrazole derivative |
EP0568096B1 (en) | 1992-04-30 | 1998-07-29 | Hodogaya Chemical Co., Ltd. | Benzothiazole derivative and agricultural and horticultural fingicide composition containing the same |
US5654322A (en) * | 1992-08-11 | 1997-08-05 | Wakunaga Seiyaku Kabushiki Kaisha | Biphenylmethane derivatives and pharmaceuticals containing the same |
JPH07507574A (ja) * | 1993-04-05 | 1995-08-24 | 藤沢薬品工業株式会社 | テストステロン5α−レダクターゼ阻害剤用インドール誘導体 |
US5395836A (en) | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
JPH06345736A (ja) | 1993-06-14 | 1994-12-20 | Tokuyama Soda Co Ltd | ウレタン化合物を製造する方法 |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
WO1995031448A1 (en) | 1994-05-17 | 1995-11-23 | Dowelanco | N-(5-isothiazolyl)amide pesticides |
EP1221307B1 (en) | 1994-07-08 | 2010-02-17 | ev3 Inc. | System for performing an intravascular procedure |
FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
ES2214546T3 (es) | 1995-09-15 | 2004-09-16 | PHARMACIA & UPJOHN COMPANY | N-oxidos de aminoariloxazolidinona. |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
US6323214B1 (en) * | 1997-10-29 | 2001-11-27 | Medco Research, Inc | Allosteric adenosine receptor modulators |
US6358992B1 (en) * | 1998-11-25 | 2002-03-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
PT1171437E (pt) | 1999-04-20 | 2004-03-31 | Syngenta Ltd | Pesticidas derivados de indazole ou benzotriazole |
DE19928033A1 (de) | 1999-06-18 | 2000-12-21 | Basf Ag | Verwendung von cyclischen Enaminen als Lichtschutzmittel |
FR2796643B1 (fr) | 1999-07-22 | 2005-04-29 | Sod Conseils Rech Applic | Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique |
GB9918037D0 (en) * | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
ES2222919T3 (es) | 1999-08-27 | 2005-02-16 | Abbott Laboratories | Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2. |
CA2384757A1 (en) | 1999-09-14 | 2001-03-22 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
AU1095101A (en) | 1999-10-18 | 2001-04-30 | University Of Connecticut, The | Cannabimimetic indole derivatives |
GB0002034D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
GB0002032D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
GB0006289D0 (en) * | 2000-03-15 | 2000-05-03 | Smithkline Beecham Plc | New use |
GB0010437D0 (en) | 2000-04-28 | 2000-06-14 | Darwin Discovery Ltd | Process |
CN1944417A (zh) | 2000-06-30 | 2007-04-11 | 大日本住友制药株式会社 | 五元环化合物 |
US6369052B1 (en) * | 2000-08-07 | 2002-04-09 | Georgetown University | Combination of huperzine and nicotinic compounds as a neuroprotective agent |
FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
ATE478670T1 (de) | 2001-01-29 | 2010-09-15 | Univ Connecticut | Rezeptor-selektive cannabimimetische aminoalkylindole |
US20030008807A1 (en) | 2001-06-14 | 2003-01-09 | The Regents Of The University Of California | Novel signaling pathway for the production of inflammatory pain and neuropathy |
US7949668B2 (en) * | 2001-08-20 | 2011-05-24 | Pardalis, Inc. | Common point authoring system for the complex sharing of hierarchically authored data objects in a distribution chain |
US20040259912A1 (en) * | 2001-09-28 | 2004-12-23 | Takahiro Matsumoto | Benzine derivatives, process for preparing the same and use thereof |
IL161661A0 (en) * | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
US6727247B2 (en) | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
ES2270080T3 (es) | 2002-05-16 | 2007-04-01 | Bayer Cropscience Gmbh | Derivados de piridincarboxamida pesticidas. |
JP3902523B2 (ja) * | 2002-08-05 | 2007-04-11 | 富士フイルム株式会社 | 光情報記録媒体および情報記録方法 |
US20040077617A1 (en) * | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Fused cycloalkyl amides and acids and their therapeutic applications |
FR2847899B1 (fr) | 2002-11-29 | 2006-04-28 | Sanofi Synthelabo | Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique |
US7390670B2 (en) * | 2003-02-20 | 2008-06-24 | Lumigen, Inc. | Signalling compounds and methods for detecting hydrogen peroxide |
US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
EP1640369A4 (en) | 2003-06-27 | 2007-10-31 | Dainippon Sumitomo Pharma Co | THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND |
AU2004270394A1 (en) | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
RU2361868C2 (ru) | 2003-12-08 | 2009-07-20 | Ф.Хоффманн-Ля Рош Аг | Новые производные тиазола |
GB0402357D0 (en) | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
EP1737850B1 (en) | 2004-04-19 | 2007-10-03 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
SE0401342D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
SE0401345D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
ES2325401T3 (es) | 2004-07-20 | 2009-09-03 | Symed Labs Limited | Intermedios novedosos para linezolid y compuestos relacionados. |
WO2006039164A2 (en) * | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
JPWO2006051704A1 (ja) * | 2004-11-15 | 2008-05-29 | 大正製薬株式会社 | イミン化合物 |
EP1833824B1 (en) * | 2004-12-21 | 2016-08-03 | AbbVie Inc. | 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands |
FR2880023B1 (fr) | 2004-12-23 | 2007-02-23 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique |
US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
TW200700387A (en) | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
US7674912B2 (en) * | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) * | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
EP1951678A1 (en) * | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
TW200804338A (en) | 2005-11-24 | 2008-01-16 | Astrazeneca Ab | New compounds |
KR20090018685A (ko) | 2006-05-31 | 2009-02-20 | 아보트 러보러터리즈 | 칸나비노이드 수용체 리간드로서의 티아졸 화합물 및 이의 용도 |
CA2647598A1 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
CN101479262A (zh) * | 2006-06-27 | 2009-07-08 | 艾博特公司 | 噻唑啉和唑啉衍生物及其应用方法 |
WO2008012105A1 (en) * | 2006-07-28 | 2008-01-31 | Synthon B.V. | Crystalline erlotinib |
WO2008028093A1 (en) * | 2006-08-31 | 2008-03-06 | Abbott Laboratories | Compounds as cb2 cannabinoid receptor ligands |
US7985768B2 (en) * | 2006-08-31 | 2011-07-26 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2008063781A2 (en) | 2006-10-12 | 2008-05-29 | Abbott Laboratories | Chemical compounds as cannabinoid receptor ligands |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
US9763894B2 (en) * | 2006-12-05 | 2017-09-19 | Virginia Commonwealth University | Inflammation therapy |
TW200831092A (en) * | 2006-12-21 | 2008-08-01 | Astrazeneca Ab | Therapeutic agents |
WO2008079687A1 (en) | 2006-12-22 | 2008-07-03 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands and uses thereof |
BRPI0807813A2 (pt) * | 2007-02-15 | 2014-08-05 | Hoffmann La Roche | 2-amino-oxazolinas como ligantes de taar1 |
CA2681586A1 (en) * | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US8501794B2 (en) * | 2007-04-17 | 2013-08-06 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US7872033B2 (en) * | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
CN101711253A (zh) | 2007-05-18 | 2010-05-19 | 雅培制药有限公司 | 用作大麻素受体配体的新化合物 |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
US8338623B2 (en) | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) * | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US20090105338A1 (en) * | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US8044071B2 (en) * | 2007-10-18 | 2011-10-25 | Abbott Laboratories | Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist |
US20090131363A1 (en) * | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
MX2010005649A (es) * | 2007-11-21 | 2010-08-18 | Abbott Lab | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. |
JP2011513495A (ja) * | 2008-03-11 | 2011-04-28 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
EP2331516B1 (en) * | 2008-08-15 | 2013-03-13 | Abbott Laboratories | Imine derivatives as cannabinoid receptor ligands |
US8846730B2 (en) * | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
EP2428507B1 (en) | 2008-09-16 | 2015-10-21 | AbbVie Bahamas Ltd. | Cannabinoid receptor ligands |
JP2012508176A (ja) | 2008-11-04 | 2012-04-05 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての1,2−チアゾリル誘導体 |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
CA2756178A1 (en) * | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8288428B2 (en) * | 2009-03-27 | 2012-10-16 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2010111574A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2011159785A1 (en) * | 2010-06-15 | 2011-12-22 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
-
2009
- 2009-12-15 PA PA20098854001A patent/PA8854001A1/es unknown
- 2009-12-16 JP JP2011542358A patent/JP2012512253A/ja not_active Withdrawn
- 2009-12-16 CN CN2009801565514A patent/CN102574825A/zh active Pending
- 2009-12-16 TW TW098143192A patent/TW201024291A/zh unknown
- 2009-12-16 ES ES09775056.6T patent/ES2564091T3/es active Active
- 2009-12-16 EP EP15197975.4A patent/EP3026046A1/en not_active Withdrawn
- 2009-12-16 CA CA2745459A patent/CA2745459A1/en not_active Abandoned
- 2009-12-16 MX MX2011006343A patent/MX2011006343A/es not_active Application Discontinuation
- 2009-12-16 WO PCT/US2009/068173 patent/WO2010071783A1/en active Application Filing
- 2009-12-16 US US12/639,173 patent/US8895592B2/en not_active Expired - Fee Related
- 2009-12-16 AR ARP090104914A patent/AR074691A1/es not_active Application Discontinuation
- 2009-12-16 UY UY0001032331A patent/UY32331A/es not_active Application Discontinuation
- 2009-12-16 EP EP09775056.6A patent/EP2376462B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
ES2564091T3 (es) | 2016-03-17 |
WO2010071783A8 (en) | 2011-07-21 |
CA2745459A1 (en) | 2010-06-24 |
EP3026046A1 (en) | 2016-06-01 |
US8895592B2 (en) | 2014-11-25 |
PA8854001A1 (es) | 2010-07-27 |
WO2010071783A1 (en) | 2010-06-24 |
TW201024291A (en) | 2010-07-01 |
JP2012512253A (ja) | 2012-05-31 |
EP2376462A1 (en) | 2011-10-19 |
US20100216760A1 (en) | 2010-08-26 |
MX2011006343A (es) | 2011-07-13 |
UY32331A (es) | 2010-07-30 |
EP2376462B1 (en) | 2015-12-16 |
CN102574825A (zh) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR074691A1 (es) | Derivados de tiazol como ligandos de receptores de cannabinoides | |
AR073599A1 (es) | Compuestos heterociclicos como ligandos de receptores de canabinoides | |
AR056195A1 (es) | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos | |
AR066013A1 (es) | Derivados de oxazolidinona, composiciones farmaceuticas que los contienen y su uso en el tratamiento o prevencion de una infeccion bacteriana. | |
AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
CO5690640A2 (es) | Derivados espirociclicos heterociclicos y procedimientos para su uso | |
AR055051A1 (es) | Compuestos de tiazol y oxazol y composiciones farmaceuticas que los contienen. | |
AR084366A1 (es) | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k | |
AR058198A1 (es) | Derivados de morfolina y composiciones farmaceuticas | |
NI201600170A (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR043190A1 (es) | Derivados de quinoleina como inhibidores del factor inhibidor de la migracion de macrofagos y metodos para su identificacion. sintesis y composiciones farmaceuticas. | |
AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
WO2009010660A3 (fr) | Indazoles substitues, leur preparation et leur utilisation en therapeutique | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
ES2668775T3 (es) | Compuestos tetracíclicos | |
NO20062633L (no) | Pyrazolderivater som proteinkinasemodulatorer | |
AR070584A1 (es) | Derivados de benzoxazol carboxamida como inhibidores de poli (adp- ribosa) polimerasa (parp) | |
AR096450A1 (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
AR070255A1 (es) | Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1) | |
UY32997A (es) | Derivados bencimidazol-imidazol | |
AR044294A1 (es) | N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa | |
CO6260132A2 (es) | Derivados de oxadiazol como inhibidores de dgat | |
AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
AR067442A1 (es) | Compuestos antivirales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |